|Ms. Kristi Jones R.Ph.||CEO, Pres & Director||520,87k||N/A||1963|
|Mr. John Trainer M.B.A.||Chief Financial Officer||514,67k||N/A||1974|
|Dr. Jerome Bernard Zeldis M.D., Ph.D.||Exec. VP of R&D||405,79k||N/A||1950|
|Dr. Robert Douglas Knight M.D.||Chief Medical Officer||454,77k||N/A||1951|
|Dr. Mathias Oelke Ph.D.||Chief Scientific Officer||N/A||N/A||1969|
|Mr. Karen Haslbeck||Head of HR||N/A||N/A||N/A|
|Dr. Daniel P. Bednarik||Sr. VP of Molecular Engineering & Protein Design||N/A||N/A||N/A|
|Mr. Chad Rubin||Sr. VP of Corp. Affairs||N/A||N/A||N/A|
|Dr. Jack A. Ragheb M.D., Ph.D.||Sr. VP of Translational Science||N/A||N/A||N/A|
|Mr. Matthew Schiller||Head of Bus. Devel.||N/A||N/A||N/A|
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
NexImmune, Inc.s ISS Governance QualityScore, Stand 28. Januar 2023, lautet 9. Die grundlegenden Scores sind Audit: 9, Vorstand: 9, Shareholderrechte: 8, Kompensation: 9.